Daraxonrasib phase 3 data raise stakes in pancreatic cancer

Revolution Medicines used the 2026 ASCO Annual Meeting to spotlight phase 3 results from RASolute 302, its registrational trial of daraxonrasib in previously treated metastatic pancreatic ductal adenocarcinoma. In the intent-to-treat population, the oral RAS(ON) inhibitor delivered a median overall survival of 13.2 months versus 6.7 months with investigator’s choice chemotherapy, with progression-free survival also improving and no new safety signals reported. Detailed results were presented May 31, 2026, and published simultaneously in The New England Journal of Medicine, while the company has said it plans global regulatory submissions, including a future FDA filing. (ir.revmed.com)

Why it matters: While this is a human oncology story, it matters to veterinary professionals because pancreatic cancer drug development often signals where precision oncology is heading more broadly: toward mutation-agnostic pathway targeting, oral therapies, and biomarker-driven care. Daraxonrasib is notable as a multi-selective RAS inhibitor rather than a single-mutation drug, and outside experts have described the results as potentially practice-changing in a disease with historically poor second-line outcomes. That kind of platform progress can shape comparative oncology research, translational expectations, and how veterinary teams talk with pet parents about the pace, limits, and promise of targeted cancer therapeutics. (ascopost.com)

What to watch: Watch for FDA and other regulatory filings, uptake of the newly permitted expanded access program, and readouts from the ongoing first-line RASolute 303 study. (ir.revmed.com)